In the AVALON cohort of relapsed/refractory AML treated with venetoclax plus hypomethylating agents, NPM1 and IDH1/2 mutations showed no significant impact on response or survival. These findings indicate that prognostic models for relapsed AML should consider treatment context rather than baseline mutation status.
Vetro, C., Azzali, I., Petracci, E., Papayannidis, C., Eleuteri, E., Palumbo, F.E., et al. (2026). NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort. HEMATOLOGICAL ONCOLOGY, 44(1), 1-1 [10.1002/hon.70169].
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
Azzali I.
;Papayannidis C.;Nanni J.;Simonetti G.;Todisco E.;Martinelli G.;Marconi G.
2026
Abstract
In the AVALON cohort of relapsed/refractory AML treated with venetoclax plus hypomethylating agents, NPM1 and IDH1/2 mutations showed no significant impact on response or survival. These findings indicate that prognostic models for relapsed AML should consider treatment context rather than baseline mutation status.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
HEMATO~1.PDF
accesso aperto
Tipo:
Versione (PDF) editoriale / Version Of Record
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
476.37 kB
Formato
Adobe PDF
|
476.37 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
